Frank Takkinen

Jason Wittes

Nelson Cox

- IRadimed reported **record Q2 2025 revenues of $20.4 million**, a **14% increase** over the prior year, marking its **16th consecutive quarter of record revenues**.  **[0001325618_2227901_1]** **[0001325618_2227901_3]**  GAAP diluted earnings per share for the quarter increased **18% to $0.45**.  **[0001325618_2227901_3]** 
- The company announced **FDA clearance for its new 3870 IV pump systems** on May 22, which is projected to be a seminal event driving future growth and contributing to a **$100 million revenue run rate** by 2026.  **[0001325618_2227901_1]**  The new pump's average selling price (ASP) is expected to be approximately **12% higher** than the current model.  **[0001325618_2227901_5]** 
- IRadimed **raised its full-year 2025 guidance**, now expecting revenues of **$80 million - $82.5 million** (up from $78 million - $82 million) and GAAP diluted earnings per share of **$1.60 - $1.70** (up from $1.55 - $1.65).  **[0001325618_2227901_2]** 
- For the third quarter of 2025, the company anticipates revenues between **$20.5 million - $20.9 million** and GAAP diluted earnings per share of **$0.41 - $0.45**.  **[0001325618_2227901_2]**

IRadimed Reports Record Q2 2025 Revenue, Raises Full-Year Guidance, and Receives FDA Clearance for New Pump

- IRADIMED CORPORATION reported **record revenue of $21.2 million** for the third quarter of 2025, representing a **16% increase** compared to the same period in 2024.  **[1325618_3a6fc4b875614b449373a85594d99304_0]** **[1325618_3a6fc4b875614b449373a85594d99304_2]** 
- The company achieved **record GAAP diluted EPS of $0.43** and **non-GAAP diluted EPS of $0.47** for Q3 2025, increases of 8% and 9% respectively, compared to Q3 2024.  **[1325618_3a6fc4b875614b449373a85594d99304_0]** **[1325618_3a6fc4b875614b449373a85594d99304_2]** 
- IRADIMED raised its full-year 2025 guidance, now projecting revenue between **$82.5 million and $83.5 million** and GAAP diluted EPS between **$1.68 and $1.72**.  **[1325618_3a6fc4b875614b449373a85594d99304_0]** **[1325618_3a6fc4b875614b449373a85594d99304_1]** **[1325618_3a6fc4b875614b449373a85594d99304_3]** 
- A regular quarterly cash dividend of **$0.17 per share** of common stock was declared for the fourth quarter of 2025, payable on November 25, 2025.  **[1325618_3a6fc4b875614b449373a85594d99304_0]** **[1325618_3a6fc4b875614b449373a85594d99304_1]**

IRADIMED Reports Record Q3 2025 Financial Results and Raises Full-Year Guidance

- IRADIMED CORPORATION reported **record revenue of $21.2 million** for the third quarter of 2025, a **16% increase** compared to the same period in 2024, alongside **record GAAP diluted EPS of $0.43** and **non-GAAP diluted EPS of $0.47**.  **[1325618_0001104659-25-105298_irmd-20251103xex99d1.htm:1]** **[1325618_0001104659-25-105298_irmd-20251103xex99d1.htm:2]** 
- The company **raised its full-year 2025 guidance**, now expecting revenue between **$82.5 million and $83.5 million**, GAAP diluted EPS of **$1.68 to $1.72**, and non-GAAP diluted EPS of **$1.84 to $1.88**.  **[1325618_0001104659-25-105298_irmd-20251103xex99d1.htm:1]** **[1325618_0001104659-25-105298_irmd-20251103xex99d1.htm:3]** 
- A regular quarterly cash dividend of **$0.17 per share** was declared for the fourth quarter of 2025, payable on **November 25, 2025**.  **[1325618_0001104659-25-105298_irmd-20251103xex99d1.htm:1]** 
- Limited commercial shipments of the **next-generation 3870 MRI-compatible IV infusion pump** are anticipated to begin in **December 2025**, with full U.S. commercialization in the first quarter of 2026.  **[1325618_0001104659-25-105298_irmd-20251103xex99d1.htm:1]**

IRADIMED (IRMD)